An 8-year-old boy diagnosed as Glanzmann thrombasthenia (GT) by other
center was referred to our department in March 2005. He has been
followed with GT for 4 years. He complained difficulty in breathing and
recurrent upper respiratory tract infections. We observed a big
perforation at nasal septum and granulation tissue related with
forgotten nasal tampon on nasal examination. Results of complete blood
count were as follows: hemoglobin 8.9 g/dL, mean corpuscular volume (MCV):
64 fl, white blood cell count 4800/mm3, and platelet count 321000/mm3.
He was hospitalized for cleaning of the granulation tissue. In our
patient alloimmunisation had developed due to frequently platelet
transfusion to stop resistant nasal and gingival bleedings before the
admission. The patient was operated with local anesthesia. Forgotten
tampon was removed and granulation tissue was resected. Regeneration of
septum nasi was performed. Bolus injection of Recombinant activated
factor VIIa (rFVIIa) 90 µg/kg was given immediately before
operation and three times with 2 hours intervals after the surgery. The
patient was discharged one day after without any complication.
Clinical efficacy of rFVIIa in thrombasthenic
patients is not clear. Thrombin generation is impaired in GT patients.
The ability of high-dose rFVIIa to improve thrombin generation through
direct binding to activated platelets and/or overcoming the inhibitory
effect of zymogen FVII may contribute to its therapeutic efficacy in GT
patients(1). rFVIIa is postulated to act on platelets to activate
factors IX and X and thus enhance thrombin generation. Other
experimental work has suggested that rFVIIa can restore platelet
adhesion defect by tissue factor-independent rFVIIa-mediated thrombin
formation(2). rFVIIa given as bolus injections appears to be a safe and
mostly effective alternative to platelet transfusion for the treatment
and prevention of bleeding in patients with GT, particularly for those
with antiplatelet antibodies and/or refractoriness to platelet
transfusions.
Ali Bay,
Ahmet Faik Öner,
Department of Pediatrics, Yuzuncu Yil University,
Faculty of Medicine, Van, Turkey.
E-mail: [email protected]
1. Hoffman M, Monroe DM III. A cell-based model of
hemostasis. Thromb Haemost 2001; 85: 958-965.
2. Lisman T, Moschatsis S, Adelmeijer J, Nieuwenhuis HK, De Groot
PG. Recombinant factor VIIa enhances deposition of platelets with
congenital or acquired alpha IIbeta 3 deficiency to endothelial cell
matrix and collagen under conditions of flow via tissue
factor-independent thrombin generation. Blood. 2003; 101:1864-1870.